Non-invasive dentistry method for clinical determination of bleeding time: evaluation in subjects with and without direct oral anticoagulant therapy.

Assessing bleeding duration in patients on direct oral anticoagulants (DOACs) is crucial for evaluating reversal strategies, yet no standardized methods are currently available for clinical trials. We investigated a non-invasive, reproducible bleeding model based on a routine dental cleaning procedu...

Descripción completa

Detalles Bibliográficos
Publicado en:Thrombosis Journal Vol. 23; no. 1; pp. 1 - 8
Autores principales: Pfützner, Andreas, Zimmermann, Anne, Wendling, Sophia, Jantz, Julia, Shing, Richard NG Kwet, Pilot, Jeff, Gillen, David, Invest, James C.F., Thomé, Nicole, Ernst, Claus-Peter, Willershausen, Brita
Formato: research tables/charts Journal Article
Publicado: BioMed Central 9/23/2025
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=188148527&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 188148527
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        14779560
        1D5H
      jtl: Thrombosis Journal
      issn: 14779560
      maglogo: N
    pubinfo:
      dt: 9/23/2025
      vid: 23
      iid: 1
      pid: 24147
      pub: BioMed Central
    artinfo:
      ui:
        188148527
        188148527
        188148527
        10.1186/s12959-025-00771-3
        188148527
      ppf: 1
      ppct: 7
      formats:
      tig:
        atl: Non-invasive dentistry method for clinical determination of bleeding time: evaluation in subjects with and without direct oral anticoagulant therapy.
      aug:
        au:
          Pfützner, Andreas
          Zimmermann, Anne
          Wendling, Sophia
          Jantz, Julia
          Shing, Richard NG Kwet
          Pilot, Jeff
          Gillen, David
          Invest, James C.F.
          Thomé, Nicole
          Ernst, Claus-Peter
          Willershausen, Brita
        affil: Pfützner Science & Health Institute, Haifa-Allee 18, D-55128, Mainz, Germany
      sug:
        subj:
          Noninvasive Procedures
          Bleeding Time Evaluation
          Anticoagulants Therapeutic Use
          Dentistry Methods
          Anticoagulation Reversal
          Human
          Cross Sectional Studies
          Nonexperimental Studies
          Pilot Studies
          Mouthwashes
          Gingivitis
          Female
          Male
          Adult
          Middle Age
          Aged
          Aged, 80 and Over
          Descriptive Statistics
          ROC Curve
          Funding Source
          Adult: 19-44 years
          Middle Aged: 45-64 years
          Aged: 65+ years
          Aged, 80 & over
          Female
          Male
      ab: Assessing bleeding duration in patients on direct oral anticoagulants (DOACs) is crucial for evaluating reversal strategies, yet no standardized methods are currently available for clinical trials. We investigated a non-invasive, reproducible bleeding model based on a routine dental cleaning procedure, aiming to provide a clinically meaningful endpoint for testing DOAC antidots. We enrolled 90 subjects in this prospective observational pilot study: 49 not receiving DOACs (group 1; 30 female, 19 male; mean age: 40.7 ± 16 years) and 41 on DOACs (group 2; 22 female, 19 male; mean age: 71.3 ± 20.4 years). Mouth-rinse samples were collected before and at 5-minute intervals for up to 60 min following bleeding-on-probing assessment, periodontal staging, and dental cleaning. Red blood cell (RBC) counts in these samples were determined using a hemocytometer. Bleeding cessation was defined as an RBC count below 150 cells/µL. Reaching this threshold within 15 min was defined as the clinical endpoint (EP). In group 1, 83.7% reached the EP (group 1a (without gingivitis): 90.9%; group 1b (with gingivitis): 77.8%). In group 2, only 39% reached the EP (group 2a (without gingivitis): 60%; group 2b (with gingivitis): 32.3%; p < 0.001 vs. group 1). The most relevant comparison for future antidote trials is between group 1b (non-DOAC with gingivitis) and group 2b (DOAC with gingivitis; p < 0.001). This model offers a standardized, non-invasive, and clinically relevant approach to monitor bleeding in DOAC-treated patients. The defined clinical endpoint (≤ 150 RBC/µL after 15 min) could serve as a useful surrogate for evaluating the efficacy of temporary DOAC reversal agents.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N